A Eisenhardt1, A Scherag, M Kempin, K H Jöckel, H Rübben. 1. Urologische Klinik, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstraße 55, 45147, Essen, Deutschland. andreas.eisenhardt@uni-essen.de
Abstract
BACKGROUND: G protein-mediated signal transduction plays a key role in pathways of metastasis. A C/T polymorphism (dbSNP rs5443) at position 825 of the GNB3 gene has been described. Previous studies demonstrated an association between the GNB3 C825T genotype and different cancer entities. PATIENTS AND METHODS: In this report genotyping for this marker was performed in 235 prostate cancer patients and 111 healthy control subjects. Clinical follow-up data were available for a subset of 197 patients. RESULTS: Neither significant evidence for differences in genotype distributions between the prostate cancer cases and controls (odds ratio CT/TT=0.94, 95% CI 0.58-1.51, p=.82) nor evidence for genotype differences in e.g. progression-free survival in the subset of patients was observable (hazard ratio CT/TT=0.77, 95% CI 0.44-1.37, p=.38). Similar results were obtained in the subgroup of patients with primary tumor stage ≤ pT2 N0 M0 undergoing radical prostatectomy. CONCLUSION: Our data do not support an association between prostate cancer and the genotype of the GNB3 C825T polymorphism. This finding might either indicate a much smaller genetic effect undetectable with the given sample size or a possible hormone dependence of the disease superimposed on the potential effect of the GNB3 C825T genotype.
BACKGROUND: G protein-mediated signal transduction plays a key role in pathways of metastasis. A C/T polymorphism (dbSNP rs5443) at position 825 of the GNB3 gene has been described. Previous studies demonstrated an association between the GNB3C825T genotype and different cancer entities. PATIENTS AND METHODS: In this report genotyping for this marker was performed in 235 prostate cancerpatients and 111 healthy control subjects. Clinical follow-up data were available for a subset of 197 patients. RESULTS: Neither significant evidence for differences in genotype distributions between the prostate cancer cases and controls (odds ratio CT/TT=0.94, 95% CI 0.58-1.51, p=.82) nor evidence for genotype differences in e.g. progression-free survival in the subset of patients was observable (hazard ratio CT/TT=0.77, 95% CI 0.44-1.37, p=.38). Similar results were obtained in the subgroup of patients with primary tumor stage ≤ pT2 N0 M0 undergoing radical prostatectomy. CONCLUSION: Our data do not support an association between prostate cancer and the genotype of the GNB3C825T polymorphism. This finding might either indicate a much smaller genetic effect undetectable with the given sample size or a possible hormone dependence of the disease superimposed on the potential effect of the GNB3C825T genotype.
Authors: Sien-Yi Sheu; Rainer Görges; Christian Ensinger; Dietmar Ofner; Nadir R Farid; Winfried Siffert; Kurt Werner Schmid Journal: J Pathol Date: 2005-12 Impact factor: 7.996
Authors: A Gsur; G Bernhofer; S Hinteregger; G Haidinger; G Schatzl; S Madersbacher; M Marberger; C Vutuc; M Micksche Journal: Int J Cancer Date: 2000-08-01 Impact factor: 7.396
Authors: Torbjörn Söderström; Mia Wadelius; Swen-Olov Andersson; Jan-Erik Johansson; Sara Johansson; Fredrik Granath; Anders Rane Journal: Pharmacogenetics Date: 2002-06
Authors: Janet L Stanford; Elizabeth A Noonan; Lori Iwasaki; Suzanne Kolb; Robert B Chadwick; Ziding Feng; Elaine A Ostrander Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-03 Impact factor: 4.254
Authors: Ulrich H Frey; Hakan Alakus; Jeremias Wohlschlaeger; Klaus J Schmitz; Günther Winde; Hans G van Calker; Karl-Heinz Jöckel; Winfried Siffert; Kurt W Schmid Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: A H Carey; D Waterworth; K Patel; D White; J Little; P Novelli; S Franks; R Williamson Journal: Hum Mol Genet Date: 1994-10 Impact factor: 6.150